This page shows the latest Debiopharm news and features for those working in and with pharma, biotech and healthcare.
Alisporivir was originally developed by Debiopharm of Switzerland and is a cyclophilin inhibitor that is thought to interfere with proteins the hepatitis C virus needs for replication. ... Novartis licensed rights to alisporivir (formerly Deb 025) from
At the moment its lead candidate is first-in-class cyclophilin inhibitor DEB025 (alisporivir), licensed from Swiss biotech Debiopharm, which works by blocking part of the replication process within the NS5A
Meanwhile, a range of other new HCV drugs are coming through the pharma industry's pipelines, including Novartis and Debiopharm's DEB025, Boehringer Ingelheim's BI 201335, Bristol-Myers Squibb 's
Mayne/Hospira, MN/Par and Actavis have all settled outstanding litigation regarding certain formulations of Eloxatin, currently under licence by S-A and Debiopharm.
medicine. S-A, who hold patent rights for the drug along with Swiss-based Debiopharm, did not give any other details regarding the recent settlements, including financial.
The Swiss drugmakers will make an undisclosed upfront payment to Debiopharm Group, an independent biopharmaceuticals company based in Switzerland, with Novartis receiving exclusive worldwide development and marketing rights (excluding Japan).
More from news
Approximately 0 fully matching, plus 8 partially matching documents found.
Debiopharm. Chugai. Licence. Exclusive worldwide licence to FF 284 in oncology.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Transforming healthcare through effective collaboration. Making work to feel proud of.
www.dovetailstrategies.com...